Every 10-Q that Atea Pharmaceuticals, Inc. (AVIR) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow AVIR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AVIR filings page.
Atea Pharmaceuticals is a late-stage antiviral developer reporting continued operating losses while advancing its HCV and HEV programs. For the three months ended June 30, 2026, it recorded a net loss of $32.9 million compared with $37.2 million a year earlier; for the first six months, the net loss was $78.4 million.
Cash, cash equivalents and marketable securities totaled $219.5 million as of June 30, 2026, which the company believes will fund planned operations through 2027, including completion of its Phase 3 HCV program. Second-quarter research and development expense was $28.2 million and general and administrative expense was $6.9 million, with G&A down year over year.
The lead HCV regimen, a fixed-dose combination of bemnifosbuvir and ruzasvir (BEM/RZR), achieved statistical non-inferiority to sofosbuvir/velpatasvir in the Phase 3 C-BEYOND trial, including a 93.9% sustained virologic response rate in the modified intent-to-treat population. Enrollment in the second Phase 3 trial, C-FORWARD, is complete, with topline data expected early in the first quarter of 2027 and an FDA New Drug Application targeted for the second quarter of 2027 if results are positive. Atea also initiated a Phase 1 trial of AT-587 for hepatitis E virus and maintains an unused $200 million at-the-market equity facility.
Atea Pharmaceuticals reported a Q1 2026 net loss of $45.4 million, compared with $34.3 million a year earlier, as it increased investment in late-stage antiviral programs.
Research and development expenses rose to $41.1 million, driven mainly by Phase 3 hepatitis C trials and hepatitis E preclinical work, while general and administrative costs declined to $6.9 million as the company managed overhead and stock-based compensation.
Atea ended March 31, 2026 with $256.0 million in cash, cash equivalents and marketable securities and expects this to fund operations through 2027 while it completes its global HCV Phase 3 program, advances AT-587 into a planned Phase 1 HEV study, and maintains an unused $200.0 million at-the-market stock offering facility.
Atea Pharmaceuticals (AVIR) filed its Q3 2025 10-Q, highlighting continued investment in its hepatitis C program and a strong liquidity position. The company reported a net loss of $42.0 million for the quarter and $113.5 million year-to-date, driven primarily by R&D as Phase 3 trials advance. R&D was $38.3 million in Q3, with HCV external costs a key component.
Cash, cash equivalents and marketable securities totaled $329.3 million as of September 30, 2025, and management believes this will fund operations through 2027. The balance sheet shows total assets of $343.0 million and stockholders’ equity of $315.8 million. Atea completed its $25.0 million share repurchase program in 2025, including 3,054,195 shares bought for $11.4 million in Q3. Shares outstanding were 78,126,796 as of November 10, 2025.
The Phase 3 HCV program (C-Beyond in the US/Canada and C-Forward ex-North America) began enrollment in April and June 2025. Atea maintains an at-the-market facility with Jefferies for up to $200.0 million; no shares were sold as of September 30, 2025. The company previously reduced headcount by ~25%, targeting aggregate savings of approximately $15 million through 2027.